Since his second time period began, President Donald Trump has introduced, negotiated, or floated a flurry of initiatives geared toward taming the excesses of the pharmaceutical business.
No shock. About 60% of American adults are “worried about being able to afford prescription drug costs for themselves or their families,” a current KFF nationwide ballot confirmed. Greater than 80% contemplate the value of prescribed drugs “unreasonable,” and most help elevated regulation to decrease prices. People pay about thrice as a lot as individuals in different international locations for a similar prescribed drugs.
Final July, Trump despatched letters to 17 drugmakers, demanding they voluntarily decrease drug costs. Then the president mentioned he’d negotiated with greater than a dozen pharmaceutical executives one after the other on the White Home. In December, he introduced that he had compelled them to comply with “most favored nation” pricing on Medicaid, the federal government protection for low-income People.
Then got here the unveiling of TrumpRx, a web site the place cash-paying sufferers may discover discounted medicines, and a promise to hurry biosimilar merchandise — generic variations of sure high-priced specialty medication — by reducing by way of FDA purple tape.
The scope of those grand gestures stays unsure. Nevertheless it’s actually lower than what the announcement promised, partly as a result of many particulars of the negotiations, even which medication are lined, are hazy.
White Home spokesperson Kush Desai didn’t reply queries about TrumpRx.
Medicaid already buys medication at deep reductions. And different sufferers could properly have higher choices by way of industrial drug low cost packages, which provide much more merchandise, or by way of their insurance coverage and related drug firm copayment playing cards.
So, for all Trump’s showmanship, the share of People more likely to profit from these choices stays slim, even when some individuals do come out forward.
“If it makes a difference to any patient, it’s a win,” mentioned Mark Cuban, a billionaire investor on his personal mission to deliver down drug costs. He pointed to discounted pricing on TrumpRx for branded fertility medication and GLP-1 weight reduction medication for individuals with out insurance coverage or whose plans don’t embody protection. Cuban launched the Mark Cuban Value Plus Drug Co., generally known as Value Plus Medication, in 2022 to promote medication cheaply by eliminating middlemen — shopping for from factories and promoting on to customers. A lot of the medication he sells are generics.
Aaron Kesselheim, a professor of medication at Harvard Medical College whose analysis focuses on drug costs, mentioned the Trump bulletins are “one-off agreements made for publicity purposes. They don’t change anything about the way drugs are priced.”
He added: “The agreements are opaque and unenforceable.”
It was unclear, for instance, which medication can be bought at “most favored nation” costs or how precisely that was outlined. However, clearly, not all had been.
Doing the Math
46brooklyn, a consulting agency and information venture that tracks brand-name drug costs, discovered that near 1,000 model medication went up in value in January 2026. What’s extra, 2025 had the very best variety of checklist value will increase ever. “This is not a material change, it’s business as usual,” mentioned Antonio Ciaccia, the corporate’s co-founder.
Within the first week of 2026, Pfizer raised the checklist costs of 71 medication by a median of 5% and lowered the value of just one, by 9.8%, the information venture discovered.
The largest win for sufferers has seemingly been the Trump administration’s quiet continuation of a Biden administration program: Medicare drug value negotiation for costly medication. The negotiated reductions on the preliminary 10 medication — from blood thinners to insulins to medicines for inflammatory issues — went into impact Jan. 1. With reductions in value of properly over 50% on some merchandise, the estimated $6 billion in annual financial savings allowed this system to cap Medicare sufferers’ out-of-pocket spending on Half D prescribed drugs at $2,000 for 2025 and past.
An extra 15 high-priced medication — together with common weight reduction and most cancers medication — had been topic to negotiation in 2025, with discounted Medicare costs taking impact subsequent 12 months. And 15 extra high-priced medication are set for negotiation this 12 months. All informed, the 40 negotiated drug costs are anticipated to avoid wasting Medicare properly over $20 billion a 12 months.
At the same time as these reductions take impact, drug business lobbyists have been working to restrict the impression, with some success. For instance, the One Huge Stunning Invoice Act exempts medication for uncommon ailments from negotiations.
Nonetheless, “this is historic because it’s the first time the United States has negotiated prices, like every other developed country,” Kesselheim mentioned. “And guess what? Innovation didn’t stop.”
In fact, these reductions profit solely Medicare enrollees. The newer Trump administration initiatives assist another sufferers, however they’re restricted and require data of easy methods to entry the reductions.
Trump’s One-on-Ones
The president’s televised appearances with the heads of main drug firms resulted in offers, however few, if any, will imply a lot to sufferers. For instance, after Trump met with Albert Bourla, CEO of Pfizer, the corporate introduced reductions on 30-plus medication. Bourla known as the deal “a win for American patients, a win for American leadership, and a win for Pfizer.”
The reductions are supplied through TrumpRx, which, in flip, provide coupons co-branded on GoodRx.com, which already gives low cost coupons for a lot of a whole bunch of medicines.
Pfizer made hay of the deal, asserting it was a part of Pfizer’s broader, landmark most favored nation, or MFN, settlement with the U.S. authorities, enabling sufferers to pay decrease costs for his or her prescription medicines “while strengthening America’s role as the global leader in biopharmaceutical innovation.”
Pfizer spokesperson Steven Danehy cited a press launch from September noting that the TrumpRx web site gives sufferers financial savings that “range as high as 85%.”
A lot of the checklist options brand-name medication, competing with far cheaper generic variations from different producers, such because the cholesterol-lowering drug Colestid, which TrumpRx lists for “50% off” at $127.91. Generic variations value about $17 on the Value Plus web site.
This implies the branded firms aren’t making a sacrifice by providing them at decrease prices as mirrored on Trump’s portal, mentioned Sean Tu, a patent regulation professional on the College of Alabama. “That’s a sale they would not have made if not for TrumpRx.”
Others are very outdated medication, akin to Cortef, or hydrocortisone, whose 5-milligram branded Pfizer model is listed at $45 on TrumpRx, half its checklist value of $91.80. It sells for much much less on Cuban’s Value Plus web site. Nonetheless others, such because the $607.20 HIV remedy Viracept, are helpful solely together with different medication that aren’t discounted.
Final week, TrumpRx added Amgen’s Humira, for years the world’s best-selling drug, at $950 a dose, down from an inventory value of practically $7,000. However Humira misplaced its patent safety in 2023, and biosimilars — primarily generic equivalents — have since come to market. Extra to the purpose, two of these biosimilars are listed on TrumpRx for as little as $207.60 a dose.
Since many of the TrumpRx merchandise can be found solely to clients with out insurance coverage who pay money, the arthritis drug Xeljanz’s drop from $2,277 to $1,518 a month would nonetheless go away it unaffordable.
A Few Notable Offers
The much-touted TrumpRx web site, launched Feb. 6, consists largely of Pfizer’s 30 medication (30 of roughly 85) with a smattering of reductions more likely to generate headlines.
These embody three fertility medication from EMD Serono, a subsidiary of the pharmaceutical large Merck KGaA, the costliest of which, Gonal-F, has an inventory value of $966 however is just $168 per IVF cycle utilizing a TrumpRx coupon.
They’ll save ladies hundreds of {dollars} — though the general value of fertility remedy will proceed to place them past the attain of many, since medication characterize solely a portion of the fee.
The TrumpRx reductions may scale back the $15,000-to-$25,000 value of a single fertility remedy cycle — ladies usually want two or three cycles to change into pregnant — by about 10%, mentioned Sean Tipton, spokesperson for the American Society for Reproductive Drugs. In some European international locations, every cycle prices about $3,000.
In change for decreasing these costs, EMD Serono bought tariffs lifted on its largely overseas-produced medicines. It additionally gained the correct to a sped-up FDA approval course of for a fertility drug it’s been advertising and marketing closely in Europe.
One other newsworthy providing on the positioning resulted from a take care of Novo Nordisk for Wegovy, its GLP-1 drug for weight reduction and diabetes, with the value lowered to as little as $199 a month for the pen. (Many insurers cowl such medication just for diabetes, leaving those that are curious about losing a few pounds paying out-of-pocket. Zepbound, Wegovy’s Lilly & Co. competitor, can also be on the checklist, at $299.)
Strain has been constructing on Novo and Lilly to decrease the U.S. value of their GLP-1 medication. The compounds have misplaced patent safety in India, and stress from clients shopping for abroad will seemingly improve when generic Wegovy goes on sale in Canada, for as little as $73 a month, presumably this 12 months.
In the USA, in the meantime, dozens of patents ought to preserve Wegovy generics off the market till 2039, mentioned professor Robin Feldman, a patent professional on the College of California Legislation-San Francisco. A current report from the analysis group I-Mak delved into a number of methods patent manipulation retains generics off the U.S. market lengthy after they’re accessible in European international locations and Canada.
And whereas the Trump administration has vowed to approve biosimilars extra quickly to make sure extra competitors and decrease costs, that won’t have a lot impression. The massive hurdle in getting generics and biosimilars to market is commonly not FDA approval, however the time it takes to override the thickets of patents that U.S. regulation permits producers to deploy to guard their mental property.
For instance, in 2021, the FDA authorised a generic of Otezla, a preferred drug for psoriatic arthritis, but it surely won’t hit the market till 2028. Its entry would require drugmakers to pay rebates to Medicare in the event that they charged this system greater than different developed international locations for “single source” medication and biologics. That may primarily enable the Medicare program to piggyback on different international locations that negotiate the costs of among the most costly medicines. These packages are nonetheless going by way of the rulemaking course of and, once more, would profit solely these lined by the Medicare program and solely not directly.
The typical patient-consumer, if keen to pay money, could discover some bargains. However getting the perfect deal may take a whole lot of mixing and matching, forcing sufferers to change into picky customers, eyeing offers for important medicines as they’d for a carton of milk or eggs.
Information reporter Maia Rosenfeld contributed to this text.
